NCT07747662Enrolling by invitation
Adaptive Optics Scanning Light Ophthalmoscopy (AOSLO) and Microperimetry (MP) Sub-study
Structure and Function in the Progression of Atrophic AMD: Validation of Photoreceptor Damage Observed With OCT Using AOSLO (Adaptive Optics Scanning Light Ophthalmoscopy and Microperimetry
Source: ClinicalTrials.gov · Last updated 26 Oct 2026
Brief summary (registry, in English)
This research sub-study is to evaluate if combining images from Optical Coherence Tomography (OCT) scans with Adaptive Optics Scanning Light Ophthalmoscopy (AOSLO) and Microperimetry (MP) could show a link between structural changes in the back of the eye and vision. 10 participants that were enrolled in the COmparison of Clarus and Optos Ultrawide Field Imaging Systems for Geographic Atrophy study \[NCT05961332\] will be approached to enroll. Participants may complete OCT imaging and initial assessments during an initial visit and may return for additional procedures, including microperimetry and AOSLO imaging, within a window of up to 4 weeks.
- Status (registry)
- Enrolling by invitation
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- First submitted
- 30 Jul 2026
- Start date
- 5 Nov 2026
- Primary completion date
- Feb 2027
- Lead sponsor
- University of Wisconsin, Madison
- Diseases
- Macular degeneration
- NCT number
- NCT07747662
What you commit to
- Study type: Interventional
- Planned participants: 10
- From 5 Nov 2026 to the primary completion date, Feb 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Presence of concurrent retinal disease which may confound assessment
- Additional Sub-study Exclusion Criteria:
- Prior or current treatment with intraocular injections for geographic atrophy (e.g., pegcetacoplan \[Syfovre\] or similar therapies) is not permitted.
Other illness
- Ocular media opacity or other condition(s) that, in the opinion of the investigators, may preclude imaging.
Other
- Unable to tolerate ophthalmic imaging
- Presence of neovascular AMD on optical coherence tomography (OCT) as confirmed by an ophthalmologist
- Presence of significant media opacity preventing adequate retinal imaging
- Individuals who, in the opinion of the investigator, are unable to tolerate study procedures or comply with study requirements.
Who the study is looking for
- 50 years or older and may be either male or female and may be of any race
- Established diagnosis of geographic atrophy (GA) due to age-related macular degeneration (AMD)
- GA characteristics: GA area of between 1.25 mm² and 23 mm², with seventy percent of eyes having GA area ranging from 2.5 mm² to 17.5 mm². GA may be unifocal or multifocal. GA may be subfoveal or extrafoveal, with twenty-five percent of eyes having subfoveal GA. The presence of concurrent peripapillary atrophy will not exclude participants from participation
- Willing to participate as evidenced by signing the written informed consent
- Additional Sub-study Inclusion Criteria:
- Early-stage GA defined as
- GA area of between 1.25 mm2 and 23 mm2
- GA may be unifocal or multifocal
- GA may be subfoveal or extrafoveal
- Concurrent peripapillary atrophy will not exclude participant from participation
- Phakic and pseudophakic participants are eligible for enrollment, with phakic participants prioritized when feasible.
Age in the registry: 50 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Wisconsin Coordinator of this site? Confirm its status | Madison | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.